Linagliptin Found Safe in T2DM Patients at High Cardiorenal Risk

ADA 2019--Linagliptin, the DPP-4 inhibitor, showed similar risk for first or recurrent CV events or hopspitalization vs placebo in T2DM patients with high cardiorenal risk in CARMELINA subanalysis.

Source: ConsultantLive - June 17, 2019 Category: Internal Medicine Authors: Kenneth J. Bender, PharmD, MA Tags: Cardiovascular Disease Diabetes Diabetes Type 2 Source Type: news